Osaka University Venture Capital Co., Ltd.
Made an investment in “Red Arrow Therapeutics, Inc.”
……
[Image: https://prtimes.jp/i/51435/63/resize/d51435-63-8dfec0bfb85abe9e4b32-0.png&s3=51435-63-99655323d9e5e3d50ba083cecbc7ab2f-2000×684.png ]
Made new investment in Red Arrow Therapeutics, Inc.
OUVC2 Investment Limited Partnership (hereinafter referred to as “OUVC2 Fund”), whose unlimited liability member is Osaka University Venture Capital Co., Ltd. (President: Hayami Shimizu, hereinafter referred to as “OUVC”), is Red Arrow Therapeutics, Inc.
(Representative Director and CEO: Takuya Miyazaki, hereinafter referred to as “Red Arrow Therapeutics”) made a new investment of 500,000 USD.
Aiming for social implementation of cutting-edge drug delivery technology Red Arrow Therapeutics was founded by Professor Horacio Cabral of the University of Tokyo’s Graduate School of Engineering to bring cutting-edge research results to patients. The company’s technology reversibly converts proteins into nanoparticles by encapsulating them in pH-responsive nanomicelles without impairing their properties. We have achieved this by emitting . We aim to apply drug delivery technology using pH-responsive nanopolymers to various disease areas including cancer.
Use this investment funds to advance non-clinical development, etc. Red Arrow Therapeutics will use the funds raised this time to conduct non-clinical studies to examine the efficacy and safety of its first pipeline, IL-12-encapsulating polymeric micelles, and to collaborate with pharmaceutical contract manufacturing and development
organizations. Production will also begin below. In this round, along with OUVC No. 2 Fund, Beyond Next Ventures Co., Ltd., University of Tokyo Edge Capital Partners Co., Ltd., and Keio Innovation Initiative Co., Ltd. (titles omitted, in no particular order) are underwriting Red Arrow Therapeutics’ capital increase. The business of Red Arrow Therapeutics aims to save as many patients as possible suffering from diseases such as cancer, and we will continue to support it as it has great social significance.
Overview of Red Arrow Therapeutics, Inc.
Company establishment: August 2021
Business details: Development of a drug delivery system that allows proteins that proliferate and activate immune cells in the body to reach only affected areas such as cancer.
Country Headquarters: 1 Broadway 14F, Cambridge, Massachusetts 02142 Japan Branch: 15F Toranomon Hills Tower, 1-17-1 Toranomon, Minato-ku, Tokyo Representative Director and CEO: Takuya Miyazaki
URL: https://redarrowtx.com/
More details about this release:
https://prtimes.jp/main/html/rd/p/000000063.000051435.html